Table 2.

Baseline Patient Demographics, by Cohort

A: Demographics, by Treatment Arm
	A (N=15)	B (N=17)	Total (N=32)	Fisher’s Exact p-value
Gender				1.0000
Female	6 (40.0%)	6 (35.3%)	12 (37.5%)
Male	9 (60.0%)	11 (64.7%)	20 (62.5%)
Race				0.2117
White	13 (86.7%)	17 (100.0%)	30 (93.8%)
Black or African American	2 (13.3%)	0 (0.0%)	2 (6.3%)
Ethnicity
Not Hispanic or Latino	15 (100.0%)	17 (100.0%)	32 (100.0%)
Age
N	15	17	32
Mean (SD)	75.0 (3.0)	76.3 (4.0)	75.7 (3.6)
Median	75.0	77.0	75.5
Q1, Q3	72.0, 78.0	73.0, 78.0	73.0, 78.0
Range	(71.0–81.0)	(71.0–86.0)	(71.0–86.0)
Age Group*				1.0000
70–74 years	7 (46.7%)	7 (41.2%)	14 (43.8%)
75–79 years	7 (46.7%)	7 (41.2%)	14 (43.8%)
80–84 years	1 (6.7%)	2 (11.8%)	3 (9.4%)
85+ years	0 (0.0%)	1 (5.9%)	1 (3.1%)
Age Group, condensed				1.0000
70–74 years	7 (46.7%)	7 (41.2%)	14 (43.8%)
75+ years	8 (53.3%)	10 (58.8%)	18 (56.3%)
ECOG Performance Score*				1.0000
0–1	14 (93.3%)	15 (88.2%)	29 (90.6%)
2	1 (6.7%)	2 (11.8%)	3 (9.4%)
Number of Metastatic Sites*				1.0000
1	5 (33.3%)	5 (29.4%)	10 (31.3%)
>1	10 (66.7%)	12 (70.6%)	22 (68.8%)

B: Demographics, by Age Group
	70–74 years (N=14)	75+ years (N=18)	Total (N=32)	p value
Gender				0.28
Female	7 (50.0%)	5 (27.8%)	12 (37.5%)
Male	7 (50.0%)	13 (72.2%)	20 (62.5%)
Race				1.00
White	13 (92.9%)	17 (94.4%)	30 (93.8%)
Black or African American	1 (7.1%)	1 (5.6%)	2 (6.3%)
Ethnicity
Not Hispanic or Latino	14 (100.0%)	18 (100.0%)	32 (100.0%)
ECOG Performance Score				0.57
0–1	12 (85.7%)	17 (94.4%)	29 (90.6%)
2	2 (14.3%)	1 (5.6%)	3 (9.4%)
Number of Metastatic Sites				0.71
1	5 (35.7%)	5 (27.8%)	10 (31.3%)
>1	9 (64.3%)	13 (72.2%)	22 (68.8%)

^*Stratification factors

Abbreviations: 5-FU = 5-fluorouracil, LV = leucovorin, mFOLFOX7 = modified FOLFOX (5-fluorouracil, leucovorin, oxaliplatin), XELOX = capecitabine, oxaliplatin, ECOG = Eastern Cooperative Oncology Group

Abbreviations: ECOG = Eastern Cooperative Oncology Group